MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization

Gynecologic Oncology

Volumn 73, Issue 3, 1999, Pages 372-382

  Davidson, Ben ^b   Goldberg, Iris ^b   Kopolovic, Juri ^b   Lerner Geva, Liat ^b   Gotlieb, Walter H ^b   Ben Baruch, Gilad ^b   Reich, Reuven ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NONE

Author keywords

CIN; Immunohistochemistry; MMP 2; MRNA in situ hybridization; MT1 MMP; Patient survival; Squamous cell carcinoma; TIMP 2; Uterine cervix

Indexed keywords

GELATINASE A; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGE; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA CELL; UTERINE CERVIX CARCINOMA IN SITU;

EID: 0033019235     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5381     Document Type: Article

References (50)

1. Liotta L A, Rao C N, Barsky S H. Tumor invasion and the extracellular matrix. Lab Invest. 49:1983;636-649.
2. Crawford, H, C, Matrisian, L, N: Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis14:234-245, 1994-1995.
3. Aznavoorian S, Murphy A N, Stetler-Stevenson W G, Liotta L A. Molecular aspects of tumor cell invasion and metastasis. Cancer. 71:1993;1368-1383.
4. Matrisian L M. The matrix-degrading metalloproteinases. Bioessays. 14:1992;455-463.
5. Liotta L A, Stetler-Stevenson W G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 51:1991;5054-5059s.
6. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 24:1993;209-218.
7. Furcht L T, Skubitz A PN, Fields G B. Tumor cell invasion, matrix metalloproteinases, and the dogma. Lab Invest. 70:1994;781-783.
8. Stetler-Stevenson W G. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 148:1996;1345-1350.
9. Jones J L, Walker R A. Control of matrix metalloproteinase activity in cancer. J Pathol. 183:1997;377-379.
10. Hoyhtya M, Fridman R, Komarek D, Porter J K, Stetler- Stevenson W G, Liotta L A, Liang C M. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer. 56:1994;500-505.
11. r 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 51:1991;439-444.
12. Monteagudo C, Merino M J, San J J, Liotta L A, Stetler-Stevenson W G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol. 136:1990;585-592.
13. Naylor M S, Stamp G WH, Davies B, Balkwill F R. Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer. 58:1994;50-56.
14. Poulsom R, Pignatelli M, Stetler-Stevenson W G, Liotta L A, Wright P A, Jeffery R E, Longcroft J M, Rogers L, Stamp G WH. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 141:1992;389-396.
15. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol. 142:1993;359-365.
16. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remacle A, Stetler-Stevenson W M, Birembaut P, Foidart M. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 424:1994;641-645.
17. Sier C F, Kubben F J, Ganesh S, Heerding M M, Griffioen G, Hanemaaijer R, van-Krieken J H, Lamers C B, Verspaget H W. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 74:1996;413-417.
18. Grigioni W F, D'Errico A, Fortunato C, Fiorentino M, Mancini A M, Stetler-Stevenson W G, Sobel M E, Liotta L A, Onisto M, Garbisa S. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol. 7:1994;220-225.
19. Nuovo G J, MacConnel P B, Simsir A, Valea F, French D L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55:1995;267-275.
20. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, Romanini C, Biagini G. The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement. Gynecol Oncol. 60:1996;271-276.
21. Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinase-2 and -9 in squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol. 104:1995;674-684.
22. Shima I, Sagaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, Morimatsu M. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer. 70:1992;2747-2753.
23. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT1-MMP) and with lymph node metastasis. Int J Cancer. 64:1995;355-359.
24. Brown P D, Bloxidge R E, Stuart N S, Gatter K C, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst. 85:1995;574-578.
25. Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol. 180:1996;283-289.
26. Stetler-Stevenson W G, Brown P D, Onisto M, Levy A T, Liotta L A. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor clines and human tumor tissues. J Biol Chem. 265:1990;13933-13938.
27. Murphy G, Houbrechts A, Cockett M I, Williamson R A, O'Shea M, Docherty A JP. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 30:1991;8097-8102.
28. Goldberg G I, Marmer B L, Grant G A, Eisen A Z, Wilhelm S, He C. Human 72 kDa type IV collagenase forms a complex with a tissue inhibitor of metallproteinase designated TIMP-2. Proc Natl Acad Sci USA. 86:1989;8207-8211.
29. Murphy G, Docherty A JP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 7:1992;120-125.
30. Strongin A Y, Collier I, Bannikov G, Marmer B L, Grant G A, Goldberg G I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 270:1995;5331-5338.
31. Strongin A Y, Marmer B L, Grant G A, Goldberg G I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem. 268:1993;14033-14039.
32. Ward R V, Atkinson S J, Slocombe P M, Docherty A J, Reynolds J J, Murphy G. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochym Biophys Acta. 1079:1991;242-246.
33. Okada A, Bellocq J P, Rouyer N, Chenard M P, Rio M C, Chambon P, Basset P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA. 92:1995;2730-2734.
34. Polette M, Nawrocki B, Gilles C, Sato H, Seiki M, Tournier J M, Birembaut P. MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch. 428:1996;29-35.
35. Afzal S, Lalani E N, Foulkes W D, Boyce B, Tickle S, Cardillo M R, Baker T, Pignatelli M, Stamp G WH. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest. 74:1996;406-421.
36. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 57:1997;2055-2060.
37. Gilles C, Polette M, Seiki M, Birembaut P, Thompson E W. Implication of collagen type I-induced membrane type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest. 76:1997;651-660.
38. Gilles C, Polette M, Piette J, Munaut C, Thompson E W, Birembaut P, Foidart J M. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer. 65:1996;209-213.
39. Visscher D W, Hoyhtya M, Ottosen S K, Liang C M, Sarkar F H, Crissman J D, Fridman R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer. 59:1994;339-344.
40. Rosai J. FIGO Staging for Carcinoma of the Cervix Uteri. Rosai J. Ackerman's Surgical Pathology. 1996;1367 Mosby, St. Louis.
41. Parks C S, Brigati D J, Manahan L J. Automated molecular pathology: one-hour in-situ DNA hybridization. J Histotechnol. 14:1991;219-229.
42. Reed J A, Manahan L J, Parks C S, Brigati D J. Complete one-hour immunocytochemistry based on capillary action. Biotechniques. 13:1992;434-443.
43. Greene G F, Kitadai Y, Pettaway C A, von Eschenbach A C, Bucana C D, Fidler I J. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol. 150:1997;1571-1582.
44. Giorno R. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol. 2:1984;161-166.
45. Guesdon J L, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem. 27:1979;1131-1139.
46. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb W H, Weis B, Ben-Baruch G, Reich R. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 72:1999;380-386.
47. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature (Lond). 370:1994;61-65.
48. Ohtani H, Motohashi H, Sato H, Seiki M, Nagura H. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer. 68:1996;565-570.
49. Yoshizaki T, Sato H, Maruyama Y, Murono S, Furukawa M, Park C, Seiki M. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer. 79:1997;139-144.
50. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55:1995;3263-3266.